This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy  • Adverse Effects  • Hematology/ Hematologic Malignancies  • Anemias  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2007;297:1868-1869.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Off-label use of erythropoiesis-stimulating agents (ESAs), a class of genetically engineered drugs for treatment of anemia, increases mortality and morbidity risk, warns the US Food and Drug Administration (FDA).

The warning follows publication late last year of studies suggesting that correction of anemia in patients with chronic kidney disease did not reduce the risk of cardiovascular events and that reaching a target hemoglobin level of 13.5 g/dL, compared with a target level of 11.3 g/dL, was associated with increased risk of cardiovascular events. Earlier this year, the FDA was also notified of several studies involving patients with cancer treated for anemia—studies that suggested ESAs increased various health risks.

Genetically engineered erythropoiesis-stimulating agents are used to stimulate bone marrow to produce red blood cells. (Photo credit: James A. Sullivan/Quill Graphics)

The manufacturers of ESAs are also facing criticism from some members of Congress who want the companies to suspend . . . [Full Text of this Article]

ESAs AND ANEMIA



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of Aerobic Exercise Training in Anemic Cancer Patients Receiving Darbepoetin Alfa: A Randomized Controlled Trial
Courneya et al.
The Oncologist 2008;13:1012-1020.
ABSTRACT | FULL TEXT  

Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients
Maekawa et al.
Nephrol Dial Transplant 2008;23:2329-2336.
ABSTRACT | FULL TEXT  

Anemia and Heart Failure: A New Pathway?
Francis and Kanderian
J Am Coll Cardiol 2007;50:1666-1667.
FULL TEXT  

L'expansion des indications : medecins, attention
Hebert and Stanbrook
CMAJ 2007;177:699-699.
FULL TEXT